Suppr超能文献

外显子组和免疫细胞评分分析揭示了同步原发性结直肠癌中的巨大变异性。

Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers.

机构信息

Applied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.

Department of Medical and Clinical Genetics, Medicum, University of Helsinki, Helsinki, Finland.

出版信息

Br J Cancer. 2019 Apr;120(9):922-930. doi: 10.1038/s41416-019-0427-4. Epub 2019 Mar 21.

Abstract

BACKGROUND

Approximately 4% of colorectal cancer (CRC) patients have at least two simultaneous cancers in the colon. Due to the shared environment, these synchronous CRCs (SCRCs) provide a unique setting to study colorectal carcinogenesis. Understanding whether these tumours are genetically similar or distinct is essential when designing therapeutic approaches.

METHODS

We performed exome sequencing of 47 primary cancers and corresponding normal samples from 23 patients. Additionally, we carried out a comprehensive mutational signature analysis to assess whether tumours had undergone similar mutational processes and the first immune cell score analysis (IS) of SCRC to analyse the interplay between immune cell invasion and mutation profile in both lesions of an individual.

RESULTS

The tumour pairs shared only few mutations, favouring different mutations in known CRC genes and signalling pathways and displayed variation in their signature content. Two tumour pairs had discordant mismatch repair statuses. In majority of the pairs, IS varied between primaries. Differences were not explained by any clinicopathological variable or mutation burden.

CONCLUSIONS

The study shows major diversity within SCRCs. Rather than rely on data from one tumour, our study highlights the need to evaluate both tumours of a synchronous pair for optimised targeted therapy.

摘要

背景

约 4%的结直肠癌(CRC)患者的结肠中至少有两个同时发生的癌症。由于共享环境,这些同步结直肠癌(SCRC)为研究结直肠发生提供了独特的环境。在设计治疗方法时,了解这些肿瘤在遗传上是相似还是不同至关重要。

方法

我们对 23 名患者的 47 个原发性癌症和相应的正常样本进行了外显子组测序。此外,我们进行了全面的突变特征分析,以评估肿瘤是否经历了相似的突变过程,并对 SCRC 进行了首次免疫细胞评分分析(IS),以分析单个个体中两个病变部位之间免疫细胞浸润和突变谱之间的相互作用。

结果

肿瘤对仅共享少数突变,有利于已知 CRC 基因和信号通路中的不同突变,并显示出其特征内容的变化。两个肿瘤对具有不同的错配修复状态。在大多数对中,IS 在原发性肿瘤之间存在差异。这些差异不能用任何临床病理变量或突变负担来解释。

结论

该研究表明 SCRC 内部存在较大的多样性。我们的研究强调需要评估同步对中两个肿瘤,而不是依赖一个肿瘤的数据,以优化靶向治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa05/6734647/61d4d5275f09/41416_2019_427_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验